The Clinical Landscape for Retinal Implants
What other treatments would an orbit-made artificial retina compete with, and what does that mean for its prospects?
Chapter summary
a crowded and fast-moving field.
Key takeaways
- 1
Patients losing vision from retinitis pigmentosa or age-related macular degeneration are the target of gene therapies, cell therapies, optogenetic treatments that make surviving retinal cells light-sensitive, and electronic implants that stimulate the retina or brain.
- 2
Each has advanced in the past decade, and some are approved.
- 3
An artificial retina built from protein films, LambdaVision's approach, must show advantages in safety, resolution, durability or cost to win clinical use.
Keep reading with Space access
This chapter (450 words) is part of Space & aerospace. Space access opens every chapter of all 11 Space reports, with the interactive models, Excel downloads, Ask and named Atlas records.
- Global Market Analysis: Deep Space Economy
- Space-Based Datacenters: Feasibility Study
- Commercial Space Stations: Feasibility Study
- Defence Space and Missile Defence: Golden Dome and the SDA Architecture
- Launch After Starship: Prices, Capacity and European Sovereign Launch, 2026–2035
- Satellites to Phones: Direct-to-Device Connectivity, Spectrum and Economics, 2026–2035
- Space Supply Chain Bottlenecks: Components, Minerals and Capacity, 2026–2030
- Lunar, Cislunar and Settlement Economics: What the Moon Costs and Who Pays, 2026–2060
- Earth Observation and AI Analytics: What a Square Kilometre Is Worth and Who Captures It, 2026–2035
- In-Space Manufacturing and Microgravity Biotech: Products, Platforms and Economics, 2026–2035
- Space-Based Solar Power: Physics, Costs and the Path to Firm Power from Orbit, 2026–2050
€199 a month or €1,490 a year per sector, after a 7-day free trial. Cancel any time. Need several sectors? All sectors: €999 a month.
Check the live record Space Contracts & Tender Radar · Space Claim Check (free)
Ask about this chapter
Answers drawn from every Setcoin report and the live Atlas. Each statement links to the passage behind it.
Ask is included with every subscription
Cited answers across every report and the Atlas, with follow-up questions and a hand-off to the opportunity finder.
Research for professional investors. Not investment advice, and not an offer of any security or fund interest.